Please note our new address from July 18, 2022:
GBG Forschungs GmbHDornhofstr. 1063263 Neu-IsenburgGermany
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
We are happy to present our research at the ASCO Annual meeting June 2022.
GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.
ESMO has announced that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
GBG Forschungs GmbHDornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd